問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tao-Yuan General Hospital Minisity of Health and Welfare (在職)

Division of Infectious Disease

Division of General Internal Medicine

National Taiwan University Hospital (在職)

Division of Infectious Disease

更新時間：2023-09-19

鄭健禹CHENG, CHIEN-YU
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -4 個月

  • s841060@gm.ym.edu.tw

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭健禹

List

27Cases

2022-12-15 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2025-12-01 - 2029-01-04

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2022-10-27 - 2030-01-21

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2024-05-03 - 2030-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2024-11-15 - 2033-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-11-01 - 2026-04-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated4Sites

2024-01-01 - 2025-09-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting5Sites

Terminated1Sites

2024-01-01 - 2025-09-30

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2020-06-01 - 2022-12-31

Phase I

A Phase I, Open-Label, Multi-Dose Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

  • Condition/Disease

    Anti-infectives for systemic use

  • Test Drug

    UB-421 SC (dB4C7C22-6 mAb)

Participate Sites
3Sites

Recruiting3Sites

2019-03-01 - 2023-10-07

Phase II

The HIV Functional Cure Potential of UB-421: A Phase II, Randomized, Open-label, Controlled, 48 Week, Proof of Concept Study, to Evaluate the Safety of UB-421 in Combination With Standard Antiretroviral Therapy (ART) and the Efficacy of HIV Reservoir Reduction as Compared With ART Alone in ART Stabilized HIV-1 Patients

  • Condition/Disease

    HIV-1 Infection

  • Test Drug

    UB-421

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting4Sites

陳彥旭
Kaohsiung Municipal Gangshan Hospital

未分科

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB